Pharmaceuticals & Healthcare

Breaking the European health financing taboo

Posted by:

How do we break the vicious circle of European healthcare financing? Europe has a changing demographic profile with more elderly people, more innovative new medicines and treatments, and greater consumer demand; at the same time, EU governments have less money to pay for healthcare. In a nutshell, we want what we cannot have.

On the surface, Europeans seem, a bit like the spoiled brat Veruca Salt from Charlie and the Chocolate Factory: they instinctively reject any healthcare reform which involves a ...

Continue Reading →
0

Monsanto and Myriad: deeper implications

Posted by:

When legal battles reach the Supreme Court, a fair amount of media scrutiny follows as the rulings often delve deeper into the inner meanings of the judges’ interpretations. The high-profile cases of Monsanto vs. Bowman and Myriad Genetics certainly did not go against this formula as they both brought to the forefront the issues of scope and threshold of patent protection respectively. In Monsanto, the Court upheld the principle in which the patent owner may set boundaries and limitations on ...

Continue Reading →
0

Prof. Pugatch keynote speech on the “Five megatrends in the pharmaceutical industry and its implications for emerging markets”

Posted by:

Prof. Pugatch keynote speech on the “five megatrends in the pharmaceutical industry and its implications for emerging markets”, at the 19th Annual International Russian Pharmaceutical Forum, St. Petersburg, 21-23 May 2013 http://www.adamsmithconferences.com/en/event/pharma-industry-russia

Continue Reading →
0

Pugatch Consilium at the Life Sciences Invest conference in Russia

Posted by:

Pugatch Consilium is organizing a panel discussion on IPRs at the Life Sciences Invest conference and partnering forum taking place November 29 and 30 in St Petersburg, Russia.

The panel discussion, titled “Intellectual property rights and pharmaceuticals – possibilities and limitations”, will focus on economic functions and benefits of pharmaceutical IPRs and the current IP-related opportunities and challenges in the Russian market. Speakers include local and international experts from from academia, industry and government.

To read more, please see Continue Reading →

0

If it’s not my innovation it’s not worth protecting, although certainly worth using! India declares war on foreign pharmaceutical innovators?

Posted by:

Bayer, Novartis, Roche and Pfizer all stand to lose from the current Indian philosophy towards biomedical innovation generated by foreign firms.

The recent patent revocations of Roche’s hepatitis C drug, Pegasys and Pfizer’s cancer drug, Sutent; the issue of a compulsory license on Bayer’s Nexavar; and the on-going patent dispute with Novartis over its oncology drug, Glivec, are symptoms of a much more fundamental philosophical gap between India (and some other emerging economies) and the west.

It would seem that the antiquated ...

Continue Reading →
0

International conference in Moscow explores innovation-based improvements for the Russian health care system

Posted by:

The conference, entitled “Efficient Health Care: Innovation-Based Development”,  will be held on Tuesday October 30, 2012 in Moscow, Russia. It will focus on new models for developing an efficient health care system and innovative management technologies aimed at improving the quality of social services and increase the efficiency of budgetary spending.

Participants and speakers include representatives from academia, international and Russian organizations, federal and regional ministries, foreign medical institutions and pharmaceutical companies.

Professor Meir Pugatch will speak on leveraging and enhancing biopharmaceutical ...

Continue Reading →
0

Launch of new global survey and index by Pugatch Consilium

Posted by:

The Pugatch Consilium has launched a new global survey of biopharmaceutical executives on countries’ competitiveness for investment.

The objective of the Biopharmaceutical Competitiveness and Investment (BCI) Survey is to provide a comprehensive snapshot of different countries’ attractiveness for biopharmaceutical investment, derived from the firsthand knowledge of executives and experts operating in each country. Using statistical analysis, respondents’ answers are translated into a quantitative index or score, which is then used to rank countries and benchmark their performance vis à vis other countries. Ultimately, ...

Continue Reading →
0

New Pugatch Consilium report

Posted by:

The Pugatch Consilium has released a new report, “Assembling the pharmaceutical R&D puzzle for needs in the developing world”.

Launched last week in Geneva, the report examines the opportunities and challenges associated with new and proposed delinking initiatives aimed at supplementing the existing R&D model to encourage R&D into neglected and tropical diseases (NTDs) and specific Type II diseases. It also provides a blueprint for evaluating the effectiveness of such mechanisms based on six key factors for success.

To view the full report, ...

Continue Reading →
0

The battle down under becomes global – how far reaching is the impact of Australia’s new plain packaging law?

Posted by:

Tobacco companies are challenging  the constitutionality of a law banning the display of their logos and designs on cigarette packs in Australia’s High Court. Their argument is that by appropriating valuable property – the trademarks which identify and distinguish their products – without compensating them, the government is ‘unjustly’ acquiring property. The debate has already expanded beyond Australia; the UK and New Zealand are also considering similar laws. More broadly, the important question is how such a law – which ...

Continue Reading →
0

Dr Meir Pugatch invited to speak on ACTA and access to medicines by European Parliament

Posted by:

Wide-spread protests against the ACTA in Europe have intensified what was already a heated debate over the treaty and its potential impact in the EU. While protesters have mainly focused on ACTA and the internet, policymakers at both the EU and national level have been examining the treaty’s potential effect on the international trade of generic medicines.

Ensuring access to medicines in middle and low income countries has since the late 1990s been a priority for the international community. The access ...

Continue Reading →
0
Page 5 of 6 «...23456